Rituximab in Interstitial Pneumonitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

February 28, 2018

Conditions
Lung Diseases, InterstitialPneumonitis, Interstitial
Interventions
DRUG

Rituximab

2 times 1000mg dose at 14 days interval treatment

RADIATION

Zr-89-rituximab immuno PET/CT

Immuno labeled PET/CT of the lungs

Trial Locations (1)

Unknown

St. Antonius Hospital, Nieuwegein

All Listed Sponsors
collaborator

Amsterdam UMC, location VUmc

OTHER

lead

Human Adams

OTHER

NCT02251964 - Rituximab in Interstitial Pneumonitis | Biotech Hunter | Biotech Hunter